=Voyager Therapeutics (VYGR) : positive results from Phase 1b trial of VY-AADC01 in advanced Parkinson's disease

• Stock: VYGR (NASDAQ) 
• Headquarters: Massachusetts
• Founded: 2013
• voyagertherapeutics.com

Voyager Therapeutics announces 'positive' results from its ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson's disease

Robust and durable clinical effects achieved with substantial reductions in daily oral levodopa use and other Parkinson's medications; one-time administrations of VY-AADC01 well-tolerated out to 24 months

• The results demonstrated durable, dose-dependent and time-dependent improvements across multiple measures of patients' motor function after a one-time administration of the gene therapy.
• Pivotal Phase 2-3 program on track to begin during late 2017 and to dose the first patient during the first half of 2018